Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 4.2%

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) rose 4.2% on Friday . The stock traded as high as $41.00 and last traded at $40.94. Approximately 42,345 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 1,477,604 shares. The stock had previously closed at $39.29.

Wall Street Analyst Weigh In

APLS has been the subject of several analyst reports. Wedbush raised their price objective on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Wells Fargo & Company decreased their price objective on Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating for the company in a report on Thursday, May 23rd. Jefferies Financial Group restated a “buy” rating and issued a $80.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, July 31st. UBS Group reduced their price target on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. Finally, The Goldman Sachs Group lifted their price target on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $72.13.

Apellis Pharmaceuticals Trading Up 3.7 %

The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. The stock has a market cap of $4.95 billion, a P/E ratio of -11.77 and a beta of 0.88. The business’s 50 day simple moving average is $37.82 and its two-hundred day simple moving average is $46.04.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $199.70 million for the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. Apellis Pharmaceuticals’s revenue for the quarter was up 110.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.02) earnings per share. As a group, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.28 EPS for the current year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the sale, the director now owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Future Financial Wealth Managment LLC purchased a new stake in Apellis Pharmaceuticals in the 1st quarter worth about $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Apellis Pharmaceuticals in the first quarter valued at $89,000. nVerses Capital LLC raised its holdings in shares of Apellis Pharmaceuticals by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after buying an additional 2,100 shares in the last quarter. CWA Asset Management Group LLC purchased a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at $205,000. Finally, Woodward Diversified Capital LLC bought a new position in shares of Apellis Pharmaceuticals during the fourth quarter valued at about $210,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).